NCT04414241 is a Phase 3 clinical trial of Hydroxychloroquine in SARS-CoV-2, sponsored by Universidad Peruana Cayetano Heredia.

Who is sponsoring NCT04414241?

NCT04414241 is sponsored by Universidad Peruana Cayetano Heredia.

What drugs are being tested in NCT04414241?

Interventions in NCT04414241: Hydroxychloroquine.

What condition does NCT04414241 study?

NCT04414241 studies SARS-CoV-2.

Is NCT04414241 still recruiting?

NCT04414241 is currently completed. Last updated 28 October 2021.

Last reviewed 2021-10-28 · How we verify

NCT04414241

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19

Completed Phase 3 Last updated 28 October 2021

What this trial tests

Phase 3 trial testing Hydroxychloroquine in SARS-CoV-2 in 68 participants. Completed in 23 November 2020.

Timeline

25 June 2020

Primary endpoint
23 November 2020

23 November 2020

Quick facts

Lead sponsor	Universidad Peruana Cayetano Heredia
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	68
Start date	25 June 2020
Primary completion	23 November 2020
Estimated completion	23 November 2020
Sites	3 locations across Peru

Drugs / interventions tested

Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →

Conditions studied

SARS-CoV-2 — all drugs for SARS-CoV-2 →

Sponsor

Universidad Peruana Cayetano Heredia — full company profile →

Who can join

18 and older, any sex, with SARS-CoV-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether hydroxychloroquine is an effective prophylactic regimen to prevent SARS-CoV-2 infection among healthcare workers. Participants will be randomized into two parallel groups. The first arm will evaluate the use of hydroxychloroquine every-other-day plus standard measures of protection for the prevention of SARS-CoV-2. The second arm will evaluate the use of standard measures of protection for the prevention of SARS-CoV-2. The target enrollment is 320 participants. Each study participant will be monitored for SARS-CoV-2 seroconversion in weekly visits or for the development of COVID-19 symptoms for 8 weeks.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19.
García-Albéniz X, Del Amo J, Polo R, Morales-Asencio JM, et al · · 2022 · cited 23× · PMID 35943669 · DOI 10.1007/s10654-022-00891-4
Pandemic COVID-19: Current status and challenges of antiviral therapies.
Chan W, He B, Wang X, He ML. · · 2020 · cited 8× · PMID 32837984 · DOI 10.1016/j.gendis.2020.07.001
Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.
Hong H, Friedland A, Hu M, Anstrom KJ, et al · · 2023 · cited 4× · PMID 37328184 · DOI 10.1136/bmjopen-2022-065305
Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial.
Llanos-Cuentas A, Schwalb A, Quintana JL, Delfin B, et al · · 2023 · cited 3× · PMID 36849996 · DOI 10.1186/s13104-023-06281-7

Verify or expand the search:

Other trials of Hydroxychloroquine

Trials testing the same drug.

NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07343635 — The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined · NA · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06971744 — Autophagy Maintenance (AUTOMAIN) · Phase 2 · recruiting
NCT05841758 — Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis · Phase 4 · recruiting

Other recruiting trials for SARS-CoV-2

Currently open trials in the same condition.

NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
NCT06585241 — A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations · Phase 4 · recruiting
NCT05876377 — Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data · active not recruiting
NCT05799651 — Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults · Phase 1 · active not recruiting

Other Universidad Peruana Cayetano Heredia trials

Trials by the same sponsor.

NCT06367361 — One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis · Phase 2 · not yet recruiting
NCT06989502 — Implementation of the COmmunity HEalth System InnovatiON Project in Low- and Middle- Income Countries · NA · not yet recruiting
NCT06565507 — Oxfendazole in Mild Parenchymal Brain Cysticercosis · Phase 2, PHASE3 · not yet recruiting
NCT05981378 — Genomic Approaches to Dissect Human Host-pathogen Interactions in the Amazonian Rainforest · not yet recruiting
NCT06500013 — WhatsApp Intervention to Assess the Effect of Messages in Adherence to Antiretrovirals in Young People With HIV in Peru · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04414241 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidad Peruana Cayetano Heredia
Last refreshed: 28 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04414241.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing